More importantly, Relypsa forecast higher spending in 2016 to fund the Veltassa launch. Guidance for 2016 operating expenses is $275-300 million. The company has approximately $285 million in cash on hand.
You can do the math. Relypsa will need additional financing, although the company said it was exploring ways to raise money without having to sell more stock.
In this market, investors are selling companies with financing needs.
Relypsa carries a $400 million-ish enterprise value with an approved drug on the market, yet investors shrug.
Tam T. writes. "Hi Adam, I'm a big fan of the Feuerstein-Ratain Rule. There's a company called Celator Pharmaceuticals (